Vaccines have long been used as a way to create an effective immune response against pathogens, and vaccines against bacteria and viruses form an important aspect of infection prevention.
Since there are naturally existing immune responses to melanoma, investigators have reasoned that a vaccine against melanoma might reduce the chance of melanoma recurring in patients with high-risk melanoma whose tumors have been removed.
Peptide Vaccine With Glucopyranosyl Lipid A - Stable Oil-in-Water Emulsion (GLA-SE) for Patients With Resected Melanoma: A Pilot Study
Matthew S. Block, M.D., Ph.D.
Many patients with resected melanoma have a high risk of melanoma recurrence, yet there are no systemic treatments that significantly improve patient outcomes. Researchers at Mayo Clinic have developed a vaccine in which a fragment of the melanoma-associated protein MART-1 is combined with an immune stimulant known as glucopyranosyl lipid A (GLA).
This project is a vaccine clinical trial in which high-risk melanoma patients receive three doses of the MART-1 protein fragment combined either with GLA in an oil-in-water emulsion or with an oil-in-water emulsion without GLA.
The trial is designed to test whether GLA improves the immune response to MART-1 relative to the oil-in-water emulsion alone.
The more effective vaccine preparation from this clinical trial will then be tested in a phase II clinical trial to determine whether the vaccine treatments reduce the rate of melanoma recurrence.
Call 855-776-0015 (toll-free) or complete an online contact form